Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of IBI363 plus bevacizumab versus investigator's choice therapy in previously treated advanced colorectal cancer
CTR20262820Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IBI363 in colorectal adenocarcinoma, sponsored by InnoCare Pharma. Started Jul 2026; status: active.
02
Drugs
IBI363
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20262820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262820.